Gyre Therapeutics (GYRE) Change in Intangibles (2022 - 2026)
Gyre Therapeutics (GYRE) reported Change in Intangibles of $5000.0 for Q1 2026, down 99.28% year-over-year from $699000.0 in Q1 2025, and up 225.0% on a QoQ basis from -$4000.0 in Q4 2025.
Gyre Therapeutics (GYRE) has 5 years of Change in Intangibles data on file, last reported at $5000.0 in Q1 2026.
- Quarterly Change in Intangibles fell 99.28% year-over-year to $5000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39000.0 (down 97.42% YoY) and the FY2025 annual result came in at $733000.0, down 9.84% from the prior year.
- Change in Intangibles improved to $5000.0 in Q1 2026 per GYRE's latest filing, from -$4000.0 in the prior quarter.
- Across five years, Change in Intangibles topped out at $810000.0 in Q4 2024 and bottomed at -$55.0 million in Q4 2022.
- The 5-year median for Change in Intangibles is $5000.0 (2026), against an average of -$4.9 million.
- The widest annual swing landed in 2024, when Change in Intangibles soared 80900.0%; it then slumped 100.49% in 2025.
- Tracing GYRE's Change in Intangibles over 5 years: stood at -$55.0 million in 2022, then jumped by 100.0% to $1000.0 in 2023, then soared by 80900.0% to $810000.0 in 2024, then tumbled by 100.49% to -$4000.0 in 2025, then jumped by 225.0% to $5000.0 in 2026.
- Per Business Quant, the three latest GYRE Change in Intangibles figures stand at $5000.0 (Q1 2026), -$4000.0 (Q4 2025), and $15000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 68,980.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | 5,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5,000.00 |
| Mar 31, 2026 | 5,000.00 |
| Dec 31, 2025 | -4,000.00 |
| Dec 31, 2025 | -4,000.00 |
| Sep 30, 2025 | 15,000.00 |
| Sep 30, 2025 | 15,000.00 |
| Jun 30, 2025 | 23,000.00 |
| Jun 30, 2025 | 23,000.00 |
| Mar 31, 2025 | 699,000.00 |
| Mar 31, 2025 | 699,000.00 |
| Dec 31, 2024 | 810,000.00 |
| Dec 31, 2024 | 810,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Sep 30, 2023 | 2,000.00 |
| Sep 30, 2023 | 2,000.00 |
| Jun 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 1,000.00 |
| Mar 31, 2023 | 65,000.00 |
| Mar 31, 2023 | 65,000.00 |
| Dec 31, 2022 | -54.99 Mn |
| Dec 31, 2022 | -54.99 Mn |